ライフサイエンスコーパス: I-FABP

1 I-FABP concentration was higher in the TDF versus TAF gr

2 I-FABP did not decline significantly in responders.

3 I-FABP remained at baseline through day 5 (range 0-50 ng

4 I-FABP Trp displayed two rotational correlation times, 6

5 I-FABP was inversely associated with percentage total bo

6 I-FABP was released into the peripheral circulation earl

7 I-FABP was repetitively measured in nine intestinal tran

8 ding Protein / Fatty Acid Binding Protein 2 (I-FABP/FABP2), a widely used biomarker for gut cell deat

9 CRP, TNF, sIL-6R, I-FABP, sCD14, D-dimer, and HA levels were elevated in a

10 4 I-FABP is highly homologous to that of A54 I-FABP, with the same overall three-dimensional fold tha

11 , zinc deficiency prevalence, FADS activity, I-FABP, or fecal calprotectin (all P > 0.05).

12 Admission I-FABP levels >=5.6 ng/mL were associated with a 7.4-fol

13 ystemic inflammatory response, with IL-6 and I-FABP as independent markers of disease severity and fa

14 .001); progressors also had higher IL-6 and I-FABP levels over the 5-year study period (P = .02 and

15 IL-6 and I-FABP, the latter a marker for intestinal damage, were

16 CRP, IL-6, and I-FABP were not associated with worse cognitive performa

17 d for PCTV budding activity; only L-FABP and I-FABP (23% the activity of L-FABP) were active.

18 iver fatty acid-binding protein (L-FABP) and I-FABP.

19 testinal fatty acid-binding proteins (L- and I-FABP) as well as four other proteins.

20 ciations between sCD14 and both HIV load and I-FABP, shedding new light on the relationships between

21 he correlations between HIV load, sCD14, and I-FABP.

22 rence in concentrations of serum zonulin and I-FABP was reported between patients and CG (P=0.55).

23 breastfeeding, sCD14, BDG, LBP, zonulin, and I-FABP correlated with several markers of systemic infla

24 esidues V26-N35, S53-R56, and A73-T76 of apo I-FABP were characterized by rapid hydrogen exchange, lo

25 and in the NOE-derived NMR structures of apo I-FABP.

26 holo-I-FABP, the structure ensemble for apo-I-FABP exhibited variability in a discrete region of the

27 ability represented backbone disorder in apo-I-FABP.

28 re, the 1.2-A X-ray crystal structure of apo-I-FABP did not exhibit this backbone disorder.

29 ver, both fecal and serum zonulin as well as I-FABP need further studies to assess their usefulness i

30 Higher baseline I-FABP levels were associated with increases in VAT, TAT

31 Average interval between I-FABP determination and biopsy was 3.4 days (SD=4.2 day

32 on, release, and targeting of fatty acids by I-FABP within the cell.

33 bility, while oleoyl CoA and CoASH decreased I-FABP Trp limiting anisotropy (order).

34 perative days 3 (baseline), 6 or 7 (elevated I-FABP), 10, and 14 (sacrifice).

35 somatic cell hybrids selected for endogenous I-FABP expression (hBRIE 380i cells) demonstrated a 5-fo

36 e amino acid mutants of the intestinal FABP (I-FABP) and determined the rate constants for binding an

37 ), liver FABP (L-FABP), and intestinal FABP (I-FABP).

38 FABP1/L-FABP, cardiac troponin I, and FABP2/I-FABP) were all drastically increased in TRIC37 C group

39 ciation constants (K(FA)) of fatty acids for I-FABP.

40 A-FABP interactions were quite different for I-FABP and A-FABP proteins.

41 y a reflection of larger kappa on values for I-FABP and smaller kappa off values for H-FABP.

42 assay, we monitored the competition for free I-FABP between ANS and fatty acids and thereby extracted

43 P) was exploited to devise an assay for free I-FABP.

44 that the absolute rate of AOFA transfer from I-FABP is faster than from L-FABP.

45 The rate of AOFA transfer from I-FABP is independent of ionic strength, directly depend

46 rongly suggest that fatty acid transfer from I-FABP to membranes occurs by direct collisional interac

47 Higher I-FABP levels were associated with lower systolic blood

48 centrations (P < .001) and marginally higher I-FABP than other groups (P = .07).

49 The amide 1H/15N resonances for apo and holo I-FABP were assigned at 25 degrees C, and gradient- and

50 ajority of the residues in both apo and holo I-FABP were characterized by relatively slow hydrogen ex

51 However, unlike holo-I-FABP, the structure ensemble for apo-I-FABP exhibited

52 exerts on the functional properties of human I-FABP.

53 Immunoreactive I-FABP appears to hold significant potential as a bioche

54 reduce affinities by about 100-fold, but in I-FABP, R106A increases affinities up to 30-fold.

55 Changes in I-FABP (p = 0.002), faecal alpha-1 antitrypsin (p = 0.01

56 80i cells) demonstrated a 5-fold increase in I-FABP transcripts in response to PYY (within 6 h) that

57 An overall 1.7-fold increase in I-FABP was observed throughout 96 weeks, with no differe

58 Minor increases in I-FABP were often associated with histologically normal

59 However, oleic acid and CoASH increased I-FABP Trp segmental mobility, while oleoyl CoA and CoAS

60 Early ART was associated with increased I-FABP levels but normalization of TNF, sIL-6R, and D-di

61 yte fatty acid binding proteins, intestinal (I-FABP) and liver (L-FABP), was examined by time-resolve

62 yte (A-FABP), heart (H-FABP), and intestine (I-FABP) were determined by using stopped-flow fluorometr

63 infants had higher sCD14 and IL-6 but lower I-FABP than HIV-exposed and HIV-unexposed infants (P < .

64 egression revealed a negative association of I-FABP with LAZ of the study participants.

65 linear correlation with the concentration of I-FABP, a protein that is thought to transport fatty aci

66 The sustained expression of I-FABP transcripts in the villar tips suggests (unlike L

67 tion in physical terms of the interaction of I-FABP with fatty acids.

68 ve therapy initiated when elevated levels of I-FABP were detected in the serum resulted in graft salv

69 g with acrylodan the Leu72 --> Ala mutant of I-FABP.

70 on correlated with the expression pattern of I-FABP mRNA in the hBRIE 380i cells where changes in tra

71 transition has implications for the role of I-FABP in cellular fatty acid transport and targeting.

72 equired element of the beta-clam topology of I-FABP.

73 -less, essentially all-beta-sheet variant of I-FABP and that the helical domain is not a required ele

74 e helical domain, we engineered a variant of I-FABP by deleting residues 15-31 and inserting a Ser-Gl

75 s study, we employed a helix-less variant of I-FABP known as delta 17-SG to investigate the role of t

76 Only I-FABP mRNA was detected in the villus tips.

77 l CoA, oleic acid, nor CoASH altered overall I-FABP rotational correlation time.

78 mined for fecal and serum zonulin and plasma I-FABP.

79 on binding to intestinal fatty acid protein (I-FABP) was exploited to devise an assay for free I-FABP

80 ereas intestinal fatty acid binding protein (I-FABP) and Endocab showed no association.

81 ices, intestinal fatty acid binding protein (I-FABP) and fecal calprotectin.

82 Intestinal fatty acid binding protein (I-FABP) and lipopolysaccharide binding protein (LBP) did

83 Intestinal fatty acid binding protein (I-FABP) arteriovenous (V-A) concentrations differences w

84 t rat intestinal fatty acid binding protein (I-FABP) at pH 5.5 and 23 degreesC, and, for comparison,

85 The intestinal fatty acid binding protein (I-FABP) belongs to a family of 15 kDa clamshell-like pro

86 human intestinal fatty acid binding protein (I-FABP) belongs to a family of intracellular lipid bindi

87 Intestinal fatty acid-binding protein (I-FABP) binds a single molecule of long-chain fatty acid

88 Intestinal fatty acid-binding protein (I-FABP) binds FFA and may be involved in their cytosolic

89 f rat intestinal fatty acid-binding protein (I-FABP) complexed with palmitate has been determined usi

90 d rat intestinal fatty acid-binding protein (I-FABP) exhibits a beta-clam topology comprised of two f

91 d rat intestinal fatty acid-binding protein (I-FABP) has been determined using triple-resonance three

92 d rat intestinal fatty acid-binding protein (I-FABP) have been characterized and compared using amide

93 , and intestinal fatty acid-binding protein (I-FABP) in order to determine the effect of soluble prot

94 arker Intestinal fatty acid binding protein (I-FABP) than IR.

95 , and intestinal fatty acid-binding protein (I-FABP) than survivors.

96 ) and intestinal fatty acid binding protein (I-FABP) were quantified by ELISA assays.

97 serum intestinal fatty acid-binding protein (I-FABP) would result in graft salvage.

98 rker (intestinal fatty acid binding protein (I-FABP)) were measured in 253 women (73% HIV-infected).

99 serum intestinal fatty acid-binding protein (I-FABP), a marker of enterocyte damage, were measured.

100 serum intestinal Fatty Acid Binding protein (I-FABP), a marker of epithelial intestinal permeability,

101 f the intestinal fatty acid-binding protein (I-FABP), at locations in the fatty acid (FA) binding sit

102 tein, intestinal fatty acid binding protein (I-FABP), is detectable in serum only after intestinal in

103 lasma intestinal fatty acid binding protein (I-FABP), soluble CD14 (sCD14), interleukin 6 (IL-6), and

104 body, intestinal fatty acid-binding protein (I-FABP), soluble CD14 (sCD14), interleukin 6 (IL-6), int

105 uding intestinal fatty acid binding protein (I-FABP), trefoil factor-3 (TFF3), lactoferrin, lipocalin

106 n the intestinal fatty acid binding protein (I-FABP), we hypothesize that ligand binding in I-BABP is

107 , and intestinal fatty acid binding protein (I-FABP).

108 , and intestinal fatty acid binding protein (I-FABP).

109 ls of intestinal fatty acid-binding protein (I-FABP/FABP2), a marker of gut damage, and of soluble CD

110 jury (intestinal fatty-acid binding protein [I-FABP] and zonula occludens-1 [ZO-1]) and microbial tra

111 , and intestinal fatty acid binding protein [I-FABP]) were measured at baseline by enzyme-linked immu

112 over (intestinal fatty acid binding protein [I-FABP]), lipopolysaccharide-induced monocyte activation

113 y acid and ileal bile acid binding proteins (I-FABP and I-BABP) were assessed over 96 weeks.

114 which shares 30% sequence identity with rat I-FABP.

115 iological concentrations of PYY can regulate I-FABP and place this peptide in a key position as part

116 associations between progression and sCD14, I-FABP, and IL-6 levels were unchanged in models control

117 nd nonprogressors, the association of sCD14, I-FABP, and IL-6 levels with liver disease progression s

118 Serum I-FABP levels do not predict clinical intestinal allogra

119 Serum I-FABP returned to baseline.

120 Serum I-FABP was measured daily until the time of sacrifice.

121 nvestigate fecal and serum zonulin and serum I-FABP in pediatric IBD patients and their correlation w

122 In untreated animals, serum I-FABP remained elevated for several days and then retur

123 Following transplantation baseline serum I-FABP (day 2 or 3) averaged < or = 10.0 ng/ml.

124 direct comparison between human A54 and T54 I-FABP has now been performed to help elucidate the stru

125 The solution structure of T54 I-FABP is highly homologous to that of A54 I-FABP, with

126 ghtly stronger binding of fatty acids to T54 I-FABP does not originate from residues in direct contac

127 formation are more sensitive to ligands than I-FABP.

128 The results clearly demonstrate that I-FABP is not essential for dietary fat absorption.

129 We tested the hypothesis that I-FABP serves an essential role in the assimilation of d

130 We propose that I-FABP functions as a lipid-sensing component of energy

131 In previously published work, we showed that I-FABP was not detectable in the serum of isografted Lew

132 Previous studies in animals suggest that I-FABP might be a useful marker of intestinal allograft

133 We obtained these constants for the I-FABP ligands oleic acid, arachidonic acid, and palmiti

134 with a more hydrophobic binding site for the I-FABP proteins.

135 parinaroyl CoA were much less ordered in the I-FABP ligand binding site than with L-FABP.

136 As, and/or CoASH differentially modulate the I-FABP and L-FABP dynamics, and the ligand binding sites

137 ith increasing FA solubility for most of the I-FABP as compared with the A-FABP proteins, consistent

138 lly, the A-FABP proteins, in contrast to the I-FABP proteins, reveal significant heat capacity change

139 atty acid is not rigidly anchored within the I-FABP binding pocket, but rather has considerable freed

140 r dichroism measurements indicated that this I-FABP variant, termed delta 17-SG, has a high beta-shee

141 Restriction of the analysis to I-FABP determinations 1 day before or on the day of biop

142 this study are consistent with FA binding to I-FABP involving an initial interaction with Arg-56 foll

143 we found in earlier work with ANS binding to I-FABP.

144 and can itself displace fatty acids bound to I-FABP.

145 These two I-FABP forms display differential binding and transport

146 pared and contrasted with those of wild-type I-FABP and a single-site mutant, R106T.

147 ion rates for both delta 17-SG and wild-type I-FABP increased with increasing oleate concentration, b

148 ociation rates for delta 17-SG and wild-type I-FABP that were comparable.

149 was less stable to denaturant than wild-type I-FABP, but the folding-unfolding transition was highly

150 erns similar to those observed for wild-type I-FABP, except for the selective absence of resonances a

151 y 20-100-fold higher than that for wild-type I-FABP.

152 ed cyclosporine (CsA, 15 mg/kg/d, p.o.) when I-FABP rose to > or = 80 ng/ml.

153 rafts, whereas rejection often occurred when I-FABP was not detectable.

154 he unbound fatty acid concentration, whereas I-FABP may be involved in the uptake and/or specific tar

155 gnose intestinal inflammation and EED, while I-FABP is negatively associated with linear growth of Ba

156 Such effects were not observed with I-FABP.

157 Then fecal and serum zonulin, I-FABP and FCP were tested by ELISA Test.